Real-World Data on First-line Treatment of Hormone Receptor-positive, HER2-negative, Metastatic Breast Cancer in Brazil

Latin American Cooperative Oncology Group308 enrolled

Overview

This study aims to describe in detail the patient journey from diagnosis to the beginning of treatment and patterns of care of hormone receptor- positive, HER2-negative de novo or recurrent metastatic breast cancer between January 2018 and December 2020 in Brazil.

Study Type

OBSERVATIONAL

Enrollment

308

Conditions

Breast Cancer

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Women ≥18 years old * Histologically confirmed hormone receptor-positive HER2-negative invasive breast cancer * Hormone receptor-positive defined as 1% to 100% of tumor nuclei positive for Estrogen - - Receptor and/or Progesterone Receptor, as per ASCO/CAP Guideline 2020 - or Allred score of ≥3 * HER2-negative defined as IHC result is 0/1+ or 2+ with ISH negative as per ASCO/CAP Guideline 2018 * Diagnosed with de novo or recurrent metastatic breast cancer between January 2018 -and December 2020 * Public health system or private health system Exclusion Criteria: * Male Breast Cancer * First-line treatment for mBC received through clinical trial

Locations (15)

CINPAM - Centro Integrado de Pesquisa da Amazônia

Manaus, Amazonas, Brazil

CRIO - Centro Regional Integrado de Oncologia

Fortaleza, Ceará, Brazil